Learn about Activase® (alteplase) treatment for acute ischemic stroke (AIS). See full safety for more information. Indications Activase (alteplase) is indicated for. Contraindications: Cathflo Activase should not be administered to patients with by a suture and lipid deposits or drug precipitates within the catheter lumen). Activase® (Alteplase) is a tissue plasminogen activator produced by recombinant .. A study of another alteplase product, Actilyse, in acute ischemic stroke, . mg vial—insert the spike end of an infusion set through the same puncture site.

Author: Salkis Mozshura
Country: Jamaica
Language: English (Spanish)
Genre: History
Published (Last): 9 March 2014
Pages: 23
PDF File Size: 10.53 Mb
ePub File Size: 18.1 Mb
ISBN: 455-4-85298-303-3
Downloads: 36727
Price: Free* [*Free Regsitration Required]
Uploader: Douzilkree

Use aseptic technique 2. Print with Office Info.

Single-Use Vial Lytic Thrombolytic – Cathflo® Activase® (alteplase)

You packag also report side effects to Genentech at The activase package insert frequent adverse reaction associated with activase package insert thrombolytics in all approved indications is bleeding.

Cathflo Activase should not be administered to patients with known hypersensitivity to alteplase or any component of the formulation. Patients who present within 3 hr of stroke symptom onset, should be treated with alteplase unless contraindications exist; longer time window Share cases and questions with Physicians on Medscape consult.

Non-Medicare Plans Medicare Plans. Adding plans inserf you to compare formulary status to other drugs in the same class. Monitor patients during and for several hours after infusion for orolingual angioedema; discontinue therapy if angioedema develops.

Print without Office Info. If arterial puncture necessary during therapy infusion, use upper extremity vessel that is accessible to manual compression, apply pressure activase package insert at least 30 min, and monitor puncture site closely.

Bleeding The most frequent adverse reaction associated iinsert all thrombolytics in all approved indications is bleeding. The interaction of Cathflo Activase with other drugs has not been formally studied.

Consider risk of reembolization from lysis of underlying deep venous thrombi in patients with pulmonary embolism. This restriction requires that specific clinical criteria be met prior to the approval of the activase package insert.

Create Your List of Plans. If catheter function restored, aspirate mL blood to remove Cathflo Activase and residual clot.


Use with caution packave benefits activase package insert risks.

FDA Internet Application Site (Accessdata) Error

Cathflo Activase has not been studied in patients known to be at risk for bleeding events that may be associated with the use activase package insert thrombolytics. The information contained in this section of the site is intended for U. Get useful tools to help you ensure and promote patency in your clinical practice.

Hold the vial of Activase upside down, position it so that the center of the stopper is directly over the exposed piercing pin of the transfer device, and push the vial of Activase down so that the piercing pin is inserted through the center of the Activase vial stopper 7.

Controlled studies in pregnant women show no evidence of fetal risk. Genentech does not recommend and does not endorse the content on any third-party activase package insert. These types of conditions should be paxkage before treatment with Cathflo Activase. Slight foaming is not unusual; let stand undisturbed for several minutes to allow large bubbles to dissipate.

Lactation There are no data inesrt presence of alteplase in human milk, effects on breastfed infant, or on milk production. Inspect parenteral drug products for particulate matter and discoloration prior to administration whenever solution and container permit. Mix by gently swirling until completely dissolved; complete dissolution occurs within 3 minutes; do NOT shake. Published studies and case reports on alteplase use activase package insert pregnant women are insufficient to inform a drug associated activase package insert of adverse developmental outcomes; alteplase is embryocidal in inseert when intravenously administered during organogenesis at clinical exposure for AMI, but no maternal or fetal toxicity was evident at lower exposure in pregnant rats or rabbits; the most common complication of thrombolytic therapy is bleeding; pregnancy may increase this risk; drug should be used activase package insert pregnancy only if potential benefit justifies potential risk to fetus.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

Quantity Limits Drugs that have quantity limits associated with each prescription. This drug is available at a higher level co-pay. Monitor patients treated with Cathflo Activase for signs of activase package insert and treat appropriately activase package insert necessary. Formulary Formulary Patient Discounts. Hypersensitivity Hypersensitivity, including urticaria, angioedema and anaphylaxis, has been reported in association with use activase package insert Cathflo Activase.


Reconstitute 2 mg vial by adding 2. Caution should be exercised with patients who have any condition for which bleeding constitutes a significant hazard. Most commonly, these are “preferred” on formulary brand drugs. Warnings Contraindications Acute Ischemic Stroke Do not administer to treat acute ischemic stroke in the activasf situations in which the risk of bleeding is greater than the potential benefit Activaae intracranial hemorrhage Subarachnoid hemorrhage Active internal bleeding Recent within 3 months activase package insert or intraspinal surgery or serious head packxge Presence of acrivase conditions that may increase the risk of bleeding eg, some neoplasms, arteriovenous malformations, aneurysms Bleeding diathesis Current severe uncontrolled hypertension.

Contact the applicable plan provider for the most current information. Coronary thrombolysis occurs in 30 min; reaches peak response at 60 min Peak plasma time: If you log out, you will pckage required to enter your username and password the next time you visit. Metabolism Rapidly cleared from circulation by liver Metabolites: Most commonly, these are generic drugs.

Print this section Print the activasse contents of. Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Activase package insert videos and instructions for the recommended dosing and administration of Cathflo. Adverse Reactions In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis.

Invert the 2 vials so that the vial of Activase is on the bottom upright and activase package insert vial of SWFI is upside-down, allowing the SWFI to flow down through the transfer device; allow the entire contents of the vial of SWFI to flow into the Activase vial approximately 0.